Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: Results from a randomized, double-blind, vehicle-controlled phase 2 study
Ruxolitinib cream demonstrated greater clinical benefit versus vehicle in patients with milder HS and had a well-tolerated safety profile.
Authors
- Melinda Gooderham (ORCID: https://orcid.org/0000-0001-8926-0113)
- M. Celeste Ferreira‐Cornwell
- Martina Lee Porter (ORCID: https://orcid.org/0000-0002-4738-4385)
- Mingyue Wang (ORCID: https://orcid.org/0000-0001-8317-3414)
- Haq Nawaz (ORCID: https://orcid.org/0000-0001-8888-4733)
Institutions
- Beth Israel Deaconess Medical Center (US)
- SKiN Health (CA)
- Incyte (United States) (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.jaad.2025.10.149
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00